Kyverna Therapeutics, Inc. (KYTX) Reports 1-Year Durable Responses for Miv-cel in SPS, gMG

Kyverna reported positive 12-month durability and safety data for miv-cel in SPS, supporting a rolling BLA targeted for completion in Q4 2026, and longer-term Phase 2 follow-up in gMG showing robust, durable effects up to 1.5 years. No high-grade CRS/ICANS and no IEC-HS were observed.Material Detai…